639 results on '"Dalton, William S."'
Search Results
2. 898 Demonstration of the utility of real-world progression-free survival (rwPFS) by application of an IFN-γ-related signature in a real-world cohort of patients with melanoma
3. The T Cell Immunoscore as a Reference for Biomarker Development Utilizing Real-World Data from Patients with Advanced Malignancies Treated with Immune Checkpoint Inhibitors
4. PLK1 stabilizes a MYC-dependent kinase network in aggressive B cell lymphomas
5. Cancer Biomarkers: An Invitation to the Table
6. Retraction Notice to: Coordinated Silencing of MYC-Mediated miR-29 by HDAC3 and EZH2 as a Therapeutic Target of Histone Modification in Aggressive B-Cell Lymphomas
7. A genome-based model for adjusting radiotherapy dose (GARD): a retrospective, cohort-based study
8. Abstract 5703: The immune cell state atlas analysis predicts therapeutic benefits with immune checkpoint inhibitors
9. Supplementary Data from Melphalan and Exportin 1 Inhibitors Exert Synergistic Antitumor Effects in Preclinical Models of Human Multiple Myeloma
10. Data from Melphalan and Exportin 1 Inhibitors Exert Synergistic Antitumor Effects in Preclinical Models of Human Multiple Myeloma
11. Supplementary Data from HYD1-induced increase in reactive oxygen species leads to autophagy and necrotic cell death in multiple myeloma cells
12. Data from Targeting the Fanconi Anemia/BRCA Pathway Circumvents Drug Resistance in Multiple Myeloma
13. Supplementary Figures 1-14 from Targeting the Fanconi Anemia/BRCA Pathway Circumvents Drug Resistance in Multiple Myeloma
14. Supplementary Methods and Materials from Targeting the Fanconi Anemia/BRCA Pathway Circumvents Drug Resistance in Multiple Myeloma
15. The Bone Marrow Microenvironment: Novel Targets to Circumvent Minimal Residual Disease and Drug Resistance in Multiple Myeloma
16. Genetic and Environmental Determinants in Multiple Myeloma: Implications for Therapy
17. De Novo and Acquired Resistance to Antitumor Alkylating Agents
18. Multiple Myeloma : A Story of Genes and the Environment
19. A deep learning approach utilizing clinical and molecular data for identifying prognostic biomarkers in patients treated with immune checkpoint inhibitors: An ORIEN pan-cancer study.
20. Predictors of immunotherapeutic benefits in patients with advanced melanoma and other malignancies treated with immune checkpoint inhibitors utilizing ORIEN “real-world” data.
21. New Therapeutic Approaches to Myeloma
22. Sequence of novel agents in multiple myeloma: An instrumental variable analysis
23. The phenomenon of multidrug resistance in non-Hodgkin’s lymphoma
24. A Phase II Trial of Autologous Bone Marrow Transplantation (ABMT) in Acute Leukemia with Edelfosine Purged Bone Marrow
25. Pharmacologic Modulation of Multidrug Resistance in Acute Leukemia: Results and Challenges
26. Plasma cell dependence on histone/protein deacetylase 11 reveals a therapeutic target in multiple myeloma
27. Follicular dendritic cell–dependent drug resistance of non-Hodgkin lymphoma involves cell adhesion–mediated Bim down-regulation through induction of microRNA-181a
28. microRNA expression profile and identification of miR-29 as a prognostic marker and pathogenetic factor by targeting CDK6 in mantle cell lymphoma
29. The role of P-glycoprotein in drug-resistant hematologic malignancies
30. Collaborative Biomedicine in the Age of Big Data: The Case of Cancer
31. Expression of Cytokeratin Confers Multiple Drug Resistance
32. A microenvironment-mediated c-Myc/ miR-548m/HDAC6 amplification loop in non-Hodgkin B cell lymphomas
33. An ET-CURE Pilot Project Supporting Undergraduate Training in Cancer Research, Emerging Technology, and Health Disparities
34. Personalizing Radiotherapy Prescription Dose Using Genomic Markers of Radiosensitivity and Normal Tissue Toxicity in Non-Small Cell Lung Cancer
35. Inhibition of Notch signaling induces apoptosis of myeloma cells and enhances sensitivity to chemotherapy
36. Environment-mediated drug resistance: a major contributor to minimal residual disease
37. Phase II study of pegylated liposomal doxorubicin, low-dose dexamethasone, and lenalidomide in patients with newly diagnosed multiple myeloma
38. Cell adhesion induces p27Kip1-associated cell-cycle arrest through down-regulation of the SCFSkp2 ubiquitin ligase pathway in mantle-cell and other non-Hodgkin B-cell lymphomas
39. Multiple Myeloma DREAM Challenge reveals epigenetic regulator PHF19 as marker of aggressive disease
40. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma
41. Melphalan and Exportin 1 Inhibitors Exert Synergistic Antitumor Effects in Preclinical Models of Human Multiple Myeloma
42. Role of the tumor microenvironment in mediating de novo resistance to drugs and physiological mediators of cell death
43. The Bone Marrow Microenvironment: Novel Targets to Circumvent Minimal Residual Disease and Drug Resistance in Multiple Myeloma
44. Cell adhesion-mediated drug resistance (CAM-DR) is associated with activation of NF-κB (RelB/p50) in myeloma cells
45. Safety and efficacy of the MDR inhibitor Incel (biricodar, VX-710) in combination with mitoxantrone and prednisone in hormone-refractory prostate cancer
46. A microenvironment-mediated c-Myc/miR-548m/HDAC6 amplification loop in non-Hodgkin B cell lymphomas
47. Inhibition of Bcr–Abl kinase activity by PD180970 blocks constitutive activation of Stat5 and growth of CML cells
48. Mechanisms Associated with cell Adhesion Mediated Drug Resistance (CAM-DR) in Hematopoietic Malignancies
49. Tumor microenvironment and drug resistance in hematologic malignancies
50. The creation of an integrated health-information platform: building the framework to support personalized medicine
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.